22UA:ETR
BioNTech SE - ADR
80,55 €
arrow_upward
+0,94%(+0,75) 1D
15 ოქტ, 17:35:58 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 22UA...
Open
79,40 €
High
80,80 €
Low
78,75 €
Mkt. cap
22,66 მლრდ.
Avg. vol.
26,41 ათ.
Volume
0,00
52-wk high
105,70 €
52-wk low
68,30 €
No. of employees
8 ათ.
Open
79,40 €
High
80,80 €
Low
78,75 €
Mkt. cap
22,66 მლრდ.
Avg. vol.
26,41 ათ.
Volume
0,00
52-wk high
105,70 €
52-wk low
68,30 €
No. of employees
8 ათ.
News stories
From web sources and news partners
ad-hoc-news.de
·
11 საათის წინ
Canaccord cuts target for BioNTech stock to USD 132.00
Pluang
·
1 დღის წინ
BioNTech shares drop 7.13% after trial failure raises concerns over oncology program claims
Simply Wall Street
·
1 დღის წინ
BioNTech Stock Faces Questions After Cancer Trial Missed Progression Free Survival Goal
TipRanks
·
2 დღის წინ
BioNTech Presses Ahead With BNT113 Cancer Trial After Initial Endpoint Miss
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR